As the CEO and board member of a “start-to-finish” biotech entrepreneurial venture and at-scale Fortune 100 pharma career, Ron Cooper has deep global expertise honed from working and living in five different countries. He is a mission-focused, strategic leader who has run multi-billion dollar global businesses and transacted his biotech for over $1B in value. Ron brings a unique perspective and approach in creating significant impact and delivering superior results. He architected and drove a strategic reinvention that turned a largely unknown, private, Swedish R&D-stage biotech into a NASDAQ listed, high-value organization. In addition, Ron played a pivotal role in the US and European approval of Bylvay, the first drug approved for a rare pediatric liver disease. While in big pharma, he propelled a >$4.5B recession-ravaged business through a major turnaround, erasing a 5% decline and generating 30% profit growth. With his deep experience, Ron is an asset to boards of biotech companies as an advisor on drug development, financing strategy, resource allocation, and commercial viability. He is a board member and committee chair at Generation Bio, a non-viral gene therapy company. Ron is a past director at Albireo Pharma and Genocea Biosciences, having served on every main board committee.